Abstract
The aim of this study was to evaluate the applicability of fluorine-19 magnetic resonance spectroscopy (F-19 MRS) for monitoring in vivo the conversion of 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU) after using an attenuated Salmonella Typhimurium strain recombinant to provide cytosine deaminase (TAPET-CD). The F-19 MRS measurements were done on mice bearing the human colon tumour xenograft (HCT116). The intratumoural conversion is greater when TAPET-CD/5-FC is delivered intratumourally (i.tu.) than when TAPET-CD is delivered intravenously (i.v.) and 5-FC intraperitoneally (i.p.). Repeat measurements of the same tumour also yielded important information on the tumour colonization by TAPET-CD through the correlated 5-FC to 5-FU conversion efficacy. The in vivo MRS spectra were confirmed by in vitro 19 F MRS of perchloric acid extracts of the tumour tissue. No 5-FU metabolites were detectable in vivo in the tumours. However, the in vitro measurements revealed, besides 5-FC and 5-FU, the presence of small amounts of catabolites. Finally, spectra obtained in vitro from liver extracts of tumour-bearing mice treated i. tu. with TAPET-CD/5-FC showed no 5-FU and only little amounts of catabolites. Our data illustrate most importantly the potential of F-19 MRS to monitor biologically-based treatments involving cytosine deaminase.
Original language | English |
---|---|
Pages (from-to) | 1796-1801 |
Number of pages | 6 |
Journal | British Journal of Cancer |
Volume | 89 |
Issue number | 9 |
DOIs | |
Publication status | Published - 3 Nov 2003 |
Keywords
- F-19 MRS
- 5-fluorouracil
- cytosine deaminase
- xenograft human tumour
- mouse
- recombinant bacteria
- MAGNETIC-RESONANCE-SPECTROSCOPY
- CANCER GENE-THERAPY
- CYTOSINE DEAMINASE
- IN-VIVO
- NMR-SPECTROSCOPY
- INTRATUMORAL PHARMACOKINETICS
- METHOTREXATE PRETREATMENT
- METABOLITE PATTERNS
- ANAEROBIC-BACTERIA
- PRODRUG ACTIVATION